The Medical Letter®

on Drugs and Therapeutics

Volume 68 February 16, 2026

ISSUE No. 1748

IN THIS ISSUE

Important Copyright Message

FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying, or any distribution of this material without permission to a nonsubscriber is prohibited.

Sharing a password with a nonsubscriber or otherwise making the contents of this site available to third parties is prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: Subscriptions, Site Licenses, Reprints
or call customer service at: 800-211-2769

The Medical Letter publications are protected by US and international copyright laws.
Forwarding, copying or any other distribution of this material is strictly prohibited.
For further information call: 800-211-2769

The Medical Letter®
on Drugs and Therapeutics

Volume 68 (Issue 1748) February 16, 2026

Take CME Exams

IN BRIEF

Removal of Suicidality Warning from GLP-1 Agonists for Weight Management

The FDA has requested the removal of the suicidal behavior and ideation warning from the labels of the three glucagon-like peptide-1 (GLP-1) receptor agonists approved for chronic weight management: liraglutide *(Saxenda)*, semaglutide *(Wegovy)*, and tirzepatide *(Zepbound)*. The warning was initially included in the labels of these drugs based on an increased risk of suicidal behavior and ideation observed with older drugs for weight management.[1]

Liraglutide, semaglutide, and tirzepatide are also marketed under different brand names for other indications, including treatment of type 2 diabetes, but the suicidality warning is not included in these labels.[2]

Removal of the warning was based on the results of analyses conducted by the FDA. In a meta-analysis of 91 controlled trials that included 107,901 patients, use of a GLP-1 receptor agonist was not associated with an increased risk of suicidal behavior/ideation or other psychiatric adverse events compared to placebo. An analysis of published observational and pooled studies also found that use of these drugs was not associated with an increased risk of suicidal behavior or ideation. A retrospective study of claims data and health records from the FDA Sentinel System that included 2,243,138 new users of GLP-1 receptor agonists or sodium-glucose cotransporter-2 (SGLT2) inhibitors found that use of a GLP-1 receptor agonist was not associated with an increased risk of intentional self-harm compared to use of an SGLT2 inhibitor.[1,3] Similar results have been observed in other studies.[4,5] ■

1. FDA Drug Safety Communication. FDA requests removal of suicidal behavior and ideation warning form glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications. January 13, 2026. Available at: https://bit.ly/4rd9VSP. Accessed January 29, 2026.
2. Drugs and devices for weight management. Med Lett Drugs Ther 2025; 67:121.
3. FDA Drug Safety Communication. Update on FDA's ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity. January 13, 2026. Available at: https://bit.ly/46iv5qu. Accessed January 29, 2026.
4. J Bezin et al. Suicide and suicide attempt in users of GLP-1 receptor agonists: a nationwide case-time-control study. EClinicalMedicine 2024; 80:103029.
5. H Tang et al. Glucagon-like peptide-1 receptor agonists and risk for suicidal ideation and behaviors in U.S. older adults with type 2 diabetes: a target trial emulation study. Ann Intern Med 2024; 177:1004.

PRESIDENT, EDITOR IN CHIEF: **Jean-Marie Pflomm, Pharm.D.**; *EDITOR IN CHIEF EMERITUS:* **Mark Abramowicz, M.D.**; *VICE PRESIDENT, ADMINISTRATION*: **Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School**; *ASSOCIATE EDITORS:* **Susan M. Daron, Pharm.D., Amy Faucard, MLS, Corinne Z. Morrison, Pharm.D., Michael P. Viscusi, Pharm.D.** *CONSULTING EDITORS:* **Joanna Esterow, PA-C, Mordechai Sacks, DMSc, PA-C, Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.**

CONTRIBUTING EDITORS: **Carl W. Bazil, M.D., Ph.D.**, Columbia University College of Physicians and Surgeons; **Ericka L. Crouse, Pharm.D., B.C.P.P., B.C.G.P., F.A.S.H.P., F.A.S.C.P.,** Virginia Commonwealth University; **Vanessa K. Dalton, M.D., M.P.H.**, University of Michigan Medical School; **Eric J. Epstein, M.D.**, Dartmouth Hitchcock Medical Center; **David N. Juurlink, BPhm, M.D., Ph.D.**, Sunnybrook Health Sciences Centre; **Richard B. Kim, M.D.**, University of Western Ontario; **Sandip K. Mukherjee, M.D., F.A.C.C.**, Yale School of Medicine; **Dan M. Roden, M.D.**, Vanderbilt University School of Medicine; **Esperance A.K. Schaefer, M.D., M.P.H.**, Harvard Medical School; **Arthur M. F. Yee, M.D., Ph.D., F.A.C.R.**, Weill Medical College of Cornell University

MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS: **Susie Wong**; *EDITORIAL ASSISTANT:* **Karrie Ferrara**

FULFILLMENT AND SYSTEMS MANAGER: **Cristine Romatowski**; *EXECUTIVE DIRECTOR OF SALES:* **Elaine Reaney-Tomaselli**
EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS: **Joanne F. Valentino**; *INTERIM PUBLISHER:* **Jean-Marie Pflomm, Pharm.D.**

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

Subscription Services

Address:
The Medical Letter, Inc.
2 Madison Ave, Ste 211
Larchmont, NY 10538
www.medicalletter.org

Customer Service:
Call: 800-211-2769 or 914-235-0500
Fax: 914-632-1733
E-mail: custserv@medicalletter.org

Permissions:
To reproduce any portion of this issue, please e-mail your request to:
permissions@medicalletter.org

Subscriptions (US):
1 year – $179; $65 per year for students, interns, residents, and fellows in the US and Canada.
Reprints – $45 per issue or article

Site License Inquiries:
E-mail: SubQuote@medicalletter.org
Call: 800-211-2769
Special rates available for bulk subscriptions.

Get Connected:

Copyright 2026. ISSN 1523-2859